Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed this Form 8-K on November 9, 2023, to report the completion of its acquisition of EQRx, Inc. ("EQRx") on November 9, 2023. The transaction was executed pursuant to a Merger Agreement dated July 31, 2023. Following the merger, EQRx ceased to exist as a separate legal entity and became a wholly-owned subsidiary of Revolution Medicines.
Key Financial Metrics and Transaction Terms
This filing details the terms of the acquisition rather than Revolution Medicines' standalone operating results for a specific period. Key financial terms include:
- Exchange Ratio: Each share of EQRx Common Stock was converted into the right to receive 0.1112 shares of Revolution Medicines Common Stock.
- Fractional Share Cash Payment: Fractional shares were paid in cash based on a price of $21.18 per share (the closing price of Revolution Medicines stock on November 8, 2023).
- Equity Treatment: In-the-money EQRx options were converted to Revolution Medicines stock; out-of-the-money options were terminated. EQRx restricted stock units and restricted stock were converted based on the exchange ratio.
- Warrants: Outstanding EQRx warrants were assumed by Revolution Medicines and converted to warrants exercisable for the merger consideration.
Revenue, profit, cash flow, and debt metrics for Revolution Medicines are not provided in this specific filing. Financial statements for EQRx are incorporated by reference as exhibits but are not summarized in the text of this report.
Material Changes
The primary material change is the consolidation of EQRx into Revolution Medicines. As a result:
- EQRx Common Stock and EQRx Warrants were delisted from the Nasdaq Global Market effective November 9, 2023.
- EQRx will cease filing periodic reports with the SEC.
- Revolution Medicines' capital structure has expanded to include shares issued to EQRx equityholders.
Guidance, Outlook, and Corporate Governance
Corporate Governance: In connection with the merger, Sandra J. Horning, M.D., was appointed to the Revolution Medicines Board of Directors as the EQRx designee. She was granted an option to purchase 36,800 shares and 10,500 restricted stock units, vesting over three years.
Stockholder Approval: On November 8, 2023, Revolution Medicines stockholders approved the issuance of shares to EQRx equityholders. Of 95,304,094 shares present or represented, 85,738,003 voted in favor of the Share Issuance Proposal.
Financial Reporting: Revolution Medicines will file pro forma financial information required by Item 9.01(b) of Form 8-K via an amendment no later than the 71st day after the required filing date.
Investor Verification Checklist
- Verify the final number of Revolution Medicines shares issued to EQRx stockholders in the post-merger capitalization table.
- Review the audited and unaudited financial statements of EQRx (Exhibits 99.1 and 99.2) to assess the acquired assets and liabilities.
- Monitor the upcoming amendment to this 8-K for the required pro forma financial information.
- Confirm the delisting status of EQRx securities on Nasdaq.